ANTONIO
OSUNA ORTEGA
COLABORADOR EXTRAORDINARIO
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (11)
2023
-
Post-transplant diabetes mellitus and renal cell cancer after renal transplantation
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, Núm. 6, pp. 1552-1559
2022
-
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study
Clinical transplantation, Vol. 36, Núm. 3, pp. e14550
2019
-
Prediabetes is a risk factor for cardiovascular disease following renal transplantation
Kidney International, Vol. 96, Núm. 6, pp. 1374-1380
2018
-
Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus
Kidney International Reports, Vol. 3, Núm. 6, pp. 1304-1315
-
Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial
American Journal of Transplantation, Vol. 18, Núm. 4, pp. 927-935
2016
-
Clinical evolution of post-transplant diabetes mellitus
Nephrology Dialysis Transplantation, Vol. 31, Núm. 3, pp. 495-505
2015
-
Medium-Term Renal Function in a Large Cohort of Stable Kidney Transplant Recipients Converted from Twice-Daily to Once-Daily Tacrolimus
Transplantation Direct, Vol. 1, Núm. 7, pp. E24
2012
2011
-
Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients
American Journal of Transplantation, Vol. 11, Núm. 9, pp. 1965-1971
2010
-
Heterogeneity of induction therapy in Spain: Changing patterns according to year, centre, indications and results
NDT Plus, Vol. 3, Núm. SUPPLL. 2